KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Change in Receivables (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Change in Receivables data on record, last reported at $6.0 million in Q4 2025.

  • For Q4 2025, Change in Receivables rose 356.63% year-over-year to $6.0 million; the TTM value through Dec 2025 reached $10.4 million, up 1048.08%, while the annual FY2025 figure was $10.4 million, 1048.08% up from the prior year.
  • Change in Receivables reached $6.0 million in Q4 2025 per AQST's latest filing, up from -$63000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $7.7 million in Q1 2022 and bottomed at -$8.2 million in Q3 2022.
  • Average Change in Receivables over 5 years is $517600.0, with a median of $635500.0 recorded in 2021.
  • Peak YoY movement for Change in Receivables: crashed 2132.69% in 2024, then surged 2228.57% in 2025.
  • A 5-year view of Change in Receivables shows it stood at -$1.4 million in 2021, then plummeted by 343.92% to -$6.1 million in 2022, then soared by 98.29% to -$104000.0 in 2023, then plummeted by 2132.69% to -$2.3 million in 2024, then soared by 356.63% to $6.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were $6.0 million in Q4 2025, -$63000.0 in Q3 2025, and $1.3 million in Q2 2025.